Oculomotoric Biometric Identification under the Influence of Alcohol and Fatigue

Patterns of micro- and macro-movements of the eyes are highly individual and can serve as a biometric characteristic. It is also known that both alcohol inebriation and fatigue can reduce saccadic velocity and accuracy. This prompts the question of whether changes of gaze patterns caused by alcohol consumption and fatigue impact the accuracy of oculomotoric biometric identification. We collect an eye tracking data set from 66 participants in sober, fatigued and alcohol-intoxicated states. We find that after enrollment in a rested and sober state, identity verification based on a deep neural embedding of gaze sequences is significantly less accurate when probe sequences are taken in either an inebriated or a fatigued state. Moreover, we find that fatigue and intoxication appear to randomize gaze patterns: when the model is fine-tuned for invariance with respect to inebriation and fatigue, and even when it is trained exclusively on inebriated training person, the model still performs significantly better for sober than for sleep-deprived or intoxicated subjects

Fairness in Oculomotoric Biometric Identification

Gaze patterns are known to be highly individual, and therefore eye movements can serve as a biometric characteristic. We explore aspects of the fairness of biometric identification based on gaze patterns. We find that while oculomotoric identification does not favor any particular gender and does not significantly favor by age range, it is unfair with respect to ethnicity. Moreover, fairness concerning ethnicity cannot be achieved by balancing the training data for the best-performing model

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

DeepEyedentificationLive: Oculomotoric Biometric Identification and Presentation-Attack Detection using Deep Neural Networks

We study involuntary micro-movements of both eyes, in addition to saccadic macro-movements, as biometric characteristic. We develop a deep convolutional neural network that processes binocular eye-tracking signals and verifies the viewer’s identity. In order to detect presentation attacks, we develop a model in which the movements are a response to a controlled stimulus. The model detects replay attacks by processing both the controlled but randomized stimulus and the ocular response to this stimulus. We acquire eye movement data from 150 participants, with 4 sessions per participant and conduct experiments on this new and legacy data sets with varying tracker precision and sampling rate. We observe that the model detects replay attacks reliably. For identification and identity verification, the model attains substantially lower error rates than prior work. We explore the relationships between training population size, training data volume, types of visual stimuli, number of training and enrollment sessions, interval between enrollment and probe sessions on one hand and the model performance on the other hand

Molecular MRI of atherosclerosis

Despite advances in prevention, risk assessment and treatment, coronary artery disease (CAD) remains the leading cause of morbidity and mortality in Western countries. The lion’s share is due to acute coronary syndromes (ACS), which are predominantly triggered by plaque rupture or erosion and subsequent coronary thrombosis. As the majority of vulnerable plaques does not cause a significant stenosis, due to expansive remodeling, and are rather defined by their composition and biological activity, detection of vulnerable plaques with x-ray angiography has shown little success. Non-invasive vulnerable plaque detection by identifying biological features that have been associated with plaque progression, destabilization and rupture may therefore be more appropriate and may allow earlier detection, more aggressive treatment and monitoring of treatment response. MR molecular imaging with target specific molecular probes has shown great promise for the noninvasive in vivo visualization of biological processes at the molecular and cellular level in animals and humans. Compared to other imaging modalities; MRI can provide excellent spatial resolution; high soft tissue contrast and has the ability to simultaneously image anatomy; function as well as biological tissue composition and activity

Detection of ADHD based on Eye Movements during Natural Viewing

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that is highly prevalent and requires clinical specialists to diagnose. It is known that an individual's viewing behavior, reflected in their eye movements, is directly related to attentional mechanisms and higher-order cognitive processes. We therefore explore whether ADHD can be detected based on recorded eye movements together with information about the video stimulus in a free-viewing task. To this end, we develop an end-to-end deep learning-based sequence model which we pre-train on a related task for which more data are available. We find that the method is in fact able to detect ADHD and outperforms relevant baselines. We investigate the relevance of the input features in an ablation study. Interestingly, we find that the model's performance is closely related to the content of the video, which provides insights for future experimental designs